{"id":13924,"date":"2025-12-17T15:15:06","date_gmt":"2025-12-17T15:15:06","guid":{"rendered":"https:\/\/pickbydoc.com\/first-twice-yearly-biologic-approved-for-severe-eosinophilic-asthma\/"},"modified":"2025-12-17T15:15:07","modified_gmt":"2025-12-17T15:15:07","slug":"first-twice-yearly-biologic-approved-for-severe-eosinophilic-asthma","status":"publish","type":"post","link":"https:\/\/pickbydoc.com\/?p=13924","title":{"rendered":"First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma"},"content":{"rendered":"<p>  (MedPage Today) &#8212; The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.<br \/>\nThe subcutaneous anti-interleukin&#8230;<\/p>\n<p><a href=\"https:\/\/www.medpagetoday.com\/allergyimmunology\/asthma\/119054\" target=\"_blank\" rel=\"noopener\">Read full article at source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(MedPage Today) &#8212; The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The subcutaneous anti-interleukin&#8230; Read full article at source<\/p>\n","protected":false},"author":1,"featured_media":13925,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1747],"tags":[],"class_list":["post-13924","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fitness-lifestyle"],"jetpack_publicize_connections":[],"_links":{"self":[{"href":"https:\/\/pickbydoc.com\/index.php?rest_route=\/wp\/v2\/posts\/13924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pickbydoc.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pickbydoc.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pickbydoc.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pickbydoc.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13924"}],"version-history":[{"count":0,"href":"https:\/\/pickbydoc.com\/index.php?rest_route=\/wp\/v2\/posts\/13924\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pickbydoc.com\/index.php?rest_route=\/wp\/v2\/media\/13925"}],"wp:attachment":[{"href":"https:\/\/pickbydoc.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pickbydoc.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pickbydoc.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}